{"id":"https://openalex.org/W2991428077","doi":"https://doi.org/10.1182/blood.v130.suppl_1.1365.1365","title":"Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart\u00ae, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies","display_name":"Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart\u00ae, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies","publication_year":2017,"publication_date":"2017-12-07","ids":{"openalex":"https://openalex.org/W2991428077","doi":"https://doi.org/10.1182/blood.v130.suppl_1.1365.1365","mag":"2991428077"},"language":"en","primary_location":{"id":"mag:2991428077","doi":"https://doi.org/10.1182/blood.v130.suppl_1.1365.1365","is_oa":false,"landing_page_url":"https://ashpublications.org/blood/article/130/Supplement%201/1365/116323/Preliminary-Translational-Results-from-an-Ongoing","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Blood","raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060952145","display_name":"Michael P. Rettig","orcid":"https://orcid.org/0000-0002-1091-0564","observed_orcids":["https://orcid.org/0000-0002-1091-0564"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael P. Rettig","raw_affiliation_strings":["Division of Oncology, Washington University School of Medicine, Saint Louis, MO;"],"raw_orcid":"https://orcid.org/0000-0002-1091-0564","affiliations":[{"raw_affiliation_string":"Division of Oncology, Washington University School of Medicine, Saint Louis, MO;","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054425800","display_name":"John E. Godwin","orcid":"https://orcid.org/0000-0003-3876-2505","observed_orcids":["https://orcid.org/0000-0003-3876-2505"]},"institutions":[{"id":"https://openalex.org/I2801670537","display_name":"Providence Portland Medical Center","ror":"https://ror.org/015tmw922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801670537","https://openalex.org/I4210160466","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John E. Godwin","raw_affiliation_strings":["Providence Cancer Center, Portland, OR"],"raw_orcid":"https://orcid.org/0000-0003-3876-2505","affiliations":[{"raw_affiliation_string":"Providence Cancer Center, Portland, OR","institution_ids":["https://openalex.org/I2801670537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053724616","display_name":"Norbert Vey","orcid":"https://orcid.org/0000-0001-7027-040X","observed_orcids":["https://orcid.org/0000-0001-7027-040X"]},"institutions":[{"id":"https://openalex.org/I4210150365","display_name":"Institut Paoli-Calmettes","ror":"https://ror.org/04s3t1g37","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4210150365"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Norbert Vey","raw_affiliation_strings":["Clinical Hematology, Paoli-Calmettes Institute, Marseille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Hematology, Paoli-Calmettes Institute, Marseille, France","institution_ids":["https://openalex.org/I4210150365"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067266240","display_name":"Bernard A. Fox","orcid":"https://orcid.org/0000-0002-4452-5947","observed_orcids":["https://orcid.org/0000-0002-4452-5947"]},"institutions":[{"id":"https://openalex.org/I2801670537","display_name":"Providence Portland Medical Center","ror":"https://ror.org/015tmw922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801670537","https://openalex.org/I4210160466","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bernard A. Fox","raw_affiliation_strings":["Providence Cancer Center, Portland, OR"],"raw_orcid":"https://orcid.org/0000-0002-4452-5947","affiliations":[{"raw_affiliation_string":"Providence Cancer Center, Portland, OR","institution_ids":["https://openalex.org/I2801670537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058602789","display_name":"Carmen Ballesteros\u2010Merino","orcid":"https://orcid.org/0000-0002-5073-7188","observed_orcids":["https://orcid.org/0000-0002-5073-7188"]},"institutions":[{"id":"https://openalex.org/I2801670537","display_name":"Providence Portland Medical Center","ror":"https://ror.org/015tmw922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801670537","https://openalex.org/I4210160466","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carmen Ballesteros\u2010Merino","raw_affiliation_strings":["Providence Cancer Center, Portland, OR"],"raw_orcid":"https://orcid.org/0000-0002-5073-7188","affiliations":[{"raw_affiliation_string":"Providence Cancer Center, Portland, OR","institution_ids":["https://openalex.org/I2801670537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062444950","display_name":"Carlo Bruno Bifulco","orcid":"https://orcid.org/0000-0003-1922-6977","observed_orcids":["https://orcid.org/0000-0003-1922-6977","https://orcid.org/0000-0002-6369-1721"]},"institutions":[{"id":"https://openalex.org/I2801670537","display_name":"Providence Portland Medical Center","ror":"https://ror.org/015tmw922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801670537","https://openalex.org/I4210160466","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carlo Bifulco","raw_affiliation_strings":["Providence Cancer Center, Portland, OR"],"raw_orcid":"https://orcid.org/0000-0003-1922-6977","affiliations":[{"raw_affiliation_string":"Providence Cancer Center, Portland, OR","institution_ids":["https://openalex.org/I2801670537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012481334","display_name":"Daner Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106297","display_name":"MacroGenics (United States)","ror":"https://ror.org/01hcd4187","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daner Li","raw_affiliation_strings":["MacroGenics, Inc., Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MacroGenics, Inc., Rockville, MD","institution_ids":["https://openalex.org/I4210106297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015310354","display_name":"Daniel Primo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Primo","raw_affiliation_strings":["Parque Cient\u00edfico de Madrid, Vivia Biotech, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parque Cient\u00edfico de Madrid, Vivia Biotech, Madrid, Spain","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110721391","display_name":"Joan Ballesteros","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joan Ballesteros","raw_affiliation_strings":["Parque Cient\u00edfico de Madrid, Vivia Biotech, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parque Cient\u00edfico de Madrid, Vivia Biotech, Madrid, Spain","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101571126","display_name":"Jichao Sun","orcid":"https://orcid.org/0000-0003-2321-1858","observed_orcids":["https://orcid.org/0000-0003-2321-1858"]},"institutions":[{"id":"https://openalex.org/I4210106297","display_name":"MacroGenics (United States)","ror":"https://ror.org/01hcd4187","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jichao Sun","raw_affiliation_strings":["MacroGenics, Inc., Rockville, MD"],"raw_orcid":"https://orcid.org/0000-0003-2321-1858","affiliations":[{"raw_affiliation_string":"MacroGenics, Inc., Rockville, MD","institution_ids":["https://openalex.org/I4210106297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114045721","display_name":"H\u00e9l\u00e8ne Leli\u00e8vre","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210144608","display_name":"Centre de Recherche en Canc\u00e9rologie de Marseille","ror":"https://ror.org/0494jpz02","country_code":"FR","type":"facility","lineage":["https://openalex.org/I1294671590","https://openalex.org/I154526488","https://openalex.org/I21491767","https://openalex.org/I4210096427","https://openalex.org/I4210144608","https://openalex.org/I4210150365"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"H\u00e9l\u00e8ne Leli\u00e8vre","raw_affiliation_strings":["Centre de Recherche en Canc\u00e9rologie de Marseille, Servier, Suresnes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre de Recherche en Canc\u00e9rologie de Marseille, Servier, Suresnes, France","institution_ids":["https://openalex.org/I4210144608"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042756782","display_name":"Jan E. Baughman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106297","display_name":"MacroGenics (United States)","ror":"https://ror.org/01hcd4187","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jan Baughman","raw_affiliation_strings":["MacroGenics, Inc., Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MacroGenics, Inc., Rockville, MD","institution_ids":["https://openalex.org/I4210106297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072006697","display_name":"Ross N. La Motte-Mohs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106297","display_name":"MacroGenics (United States)","ror":"https://ror.org/01hcd4187","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ross La Motte\u2010Mohs","raw_affiliation_strings":["MacroGenics, Inc., Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MacroGenics, Inc., Rockville, MD","institution_ids":["https://openalex.org/I4210106297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071994294","display_name":"JOHN B. MUTH","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106297","display_name":"MacroGenics (United States)","ror":"https://ror.org/01hcd4187","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Muth","raw_affiliation_strings":["MacroGenics, Inc., Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MacroGenics, Inc., Rockville, MD","institution_ids":["https://openalex.org/I4210106297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023294934","display_name":"Paul A. Moore","orcid":"https://orcid.org/0000-0001-6057-7539","observed_orcids":["https://orcid.org/0000-0001-6057-7539"]},"institutions":[{"id":"https://openalex.org/I4210106297","display_name":"MacroGenics (United States)","ror":"https://ror.org/01hcd4187","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul A. Moore","raw_affiliation_strings":["MacroGenics, Inc., Rockville, MD"],"raw_orcid":"https://orcid.org/0000-0001-6057-7539","affiliations":[{"raw_affiliation_string":"MacroGenics, Inc., Rockville, MD","institution_ids":["https://openalex.org/I4210106297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009027578","display_name":"Ezio Bonvini","orcid":"https://orcid.org/0000-0001-9054-3137","observed_orcids":["https://orcid.org/0000-0001-9054-3137"]},"institutions":[{"id":"https://openalex.org/I4210106297","display_name":"MacroGenics (United States)","ror":"https://ror.org/01hcd4187","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ezio Bonvini","raw_affiliation_strings":["MacroGenics, Inc., Rockville, MD"],"raw_orcid":"https://orcid.org/0000-0001-9054-3137","affiliations":[{"raw_affiliation_string":"MacroGenics, Inc., Rockville, MD","institution_ids":["https://openalex.org/I4210106297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051746857","display_name":"Jon M. Wigginton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106297","display_name":"MacroGenics (United States)","ror":"https://ror.org/01hcd4187","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jon M. Wigginton","raw_affiliation_strings":["MacroGenics, Inc., Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MacroGenics, Inc., Rockville, MD","institution_ids":["https://openalex.org/I4210106297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065066309","display_name":"John F. DiPersio","orcid":"https://orcid.org/0000-0002-0429-3133","observed_orcids":["https://orcid.org/0000-0002-0429-3133"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John F. DiPersio","raw_affiliation_strings":["Division of Oncology, Washington University School of Medicine, Saint Louis, MO;"],"raw_orcid":"https://orcid.org/0000-0002-0429-3133","affiliations":[{"raw_affiliation_string":"Division of Oncology, Washington University School of Medicine, Saint Louis, MO;","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5005194853","display_name":"Jan Kenneth Davidson-Moncada","orcid":"https://orcid.org/0000-0001-5550-8088","observed_orcids":["https://orcid.org/0000-0001-5550-8088"]},"institutions":[{"id":"https://openalex.org/I4210106297","display_name":"MacroGenics (United States)","ror":"https://ror.org/01hcd4187","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jan K. Davidson-Moncada","raw_affiliation_strings":["MacroGenics, Inc., Rockville, MD"],"raw_orcid":"https://orcid.org/0000-0001-5550-8088","affiliations":[{"raw_affiliation_string":"MacroGenics, Inc., Rockville, MD","institution_ids":["https://openalex.org/I4210106297"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":2.3225,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":{"value":0.89566519,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"130","issue":null,"first_page":"1365","last_page":"1365"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.8057000041007996,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.8057000041007996,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.17520000040531158,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.002899999963119626,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9940000176429749},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9639999866485596},{"id":"https://openalex.org/keywords/pd-1-pd-l1-inhibitors","display_name":"PD-1/PD-L1 inhibitors","score":0.9129999876022339},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.640999972820282},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7250000238418579},{"id":"https://openalex.org/keywords/interferon-gamma","display_name":"interferon-gamma","score":0.746999979019165},{"id":"https://openalex.org/keywords/pd-l1-upregulation","display_name":"PD-L1 upregulation","score":0.9559999704360962},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.7549999952316284},{"id":"https://openalex.org/keywords/t-cell-redirection","display_name":"T cell redirection","score":0.6499999761581421},{"id":"https://openalex.org/keywords/relapsed-refractory-aml","display_name":"relapsed/refractory AML","score":0.777999997138977}],"concepts":[{"id":"https://openalex.org/C83396363","wikidata":"https://www.wikidata.org/wiki/Q21116062","display_name":"Interleukin-3 receptor","level":3,"score":0.6322393417358398},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.6227302551269531},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.59751296043396},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.5095582008361816},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4644581973552704},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.4619264006614685},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.4528067111968994},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.42452919483184814},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.40242308378219604},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.38054490089416504},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3665996789932251},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3474873900413513},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3000330924987793}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2991428077","doi":"https://doi.org/10.1182/blood.v130.suppl_1.1365.1365","is_oa":false,"landing_page_url":"https://ashpublications.org/blood/article/130/Supplement%201/1365/116323/Preliminary-Translational-Results-from-an-Ongoing","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Blood","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2985247143","https://openalex.org/W2915887287","https://openalex.org/W2898689626","https://openalex.org/W2906734847","https://openalex.org/W2984983564","https://openalex.org/W3165708125","https://openalex.org/W2909830996","https://openalex.org/W3212612169","https://openalex.org/W2763755945","https://openalex.org/W4394873323"],"abstract_inverted_index":{"Abstract":[0],"Background:":[3],"Immunotherapy":[5],"has":[6,124,304],"transformed":[7],"cancer":[8],"treatment;":[9,180],"in":[10,26,52,85,91,127,147,170,176,202,230,258,313,319,324,333,366,371,402],"particular,":[11],"checkpoint":[12],"inhibitors":[13,117],"(CPI)":[14],"are":[15],"now":[16],"approved":[17],"for":[18],"the":[19,39,74,111,325,348,398],"treatment":[20,269,356],"of":[21,41,57,76,114,138,151,161,187,200,209,227,247,274,282,292,307,339,357,400,461,471],"several":[22],"solid":[23],"tumors":[24],"and":[25,95,155,192,322,344,364,432,468],"patients":[27,92,128,232,261,283,372,404],"with":[28,93,98,118,129,149,172,182,196,207,222,234,244,284,316,328,361,378,393,405],"Hodgkin's":[29],"disease.":[30],"In":[31,205],"hematological":[32],"malignancies,":[33],"including":[34],"acute":[35],"myeloid":[36],"leukemia":[37],"(AML),":[38],"utility":[40],"CPIs":[42],"may":[43,335,396],"be":[44,383],"more":[45],"limited":[46],"due":[47],"to":[48,73,109,135,143,255,337,382],"less":[49,253],"mutations":[50],"observed":[51,215,354],"their":[53],"genomes.":[54],"Immunologic":[55],"treatments":[56],"hematologic":[58,66],"malignancies":[59],"targeting":[60],"\u201cshared\u201d":[61],"epitopes":[62],"differentially":[63],"overexpressed":[64],"by":[65,212,347],"cancers":[67],"also":[68],"represents":[69],"a":[70,101,173,280],"rational":[71],"approach":[72],"immunotherapy":[75],"AML.":[77,409],"Methods:":[79],"Translational":[81],"studies":[82],"were":[83,252],"performed":[84],"an":[86,317,458],"ongoing":[87],"phase":[88],"1":[89],"study":[90,167],"AML":[94,131,145,219,238,242,277,295,311,349,358,369],"MDS":[96],"treated":[97],"flotetuzumab":[99,169,268,288,363,376,401],"(MGD006/S80880),":[100],"novel":[102],"CD123":[103],"x":[104],"CD3":[105],"bispecific":[106],"DART\u00ae":[107],"protein,":[108],"assess":[110],"potential":[112],"role":[113],"combining":[115],"PD-1/PD-L1":[116],"flotetuzumab.":[119],"Results:":[121],"Flotetuzumab":[123,303],"anti-leukemic":[125],"activity":[126,308],"relapsed/refractory":[130],"(ESMO":[132],"2017).":[133],"Inherent":[134],"flotetuzumab's":[136],"mode":[137],"action":[139],"is":[140],"redirecting":[141],"T-cells":[142,178,194],"lyse":[144],"cells":[146,343,370],"conjunction":[148],"enhancement":[150],"T-cell":[152,320],"activation,":[153],"proliferation":[154],"cytokine":[156],"production.":[157],"Multispectral":[158],"immunohistochemistry":[159],"analysis":[160],"bone":[162,326],"marrow":[163],"samples":[164,243],"from":[165],"our":[166],"showed":[168,289],"situ":[171],"~2-fold":[174],"increase":[175,318],"CD8":[177,193],"upon":[179],"consistent":[181],"this,":[183],"we":[184,214],"observe":[185],"up-regulation":[186],"PD-1":[188,340],"on":[189,218,237,249,267,276,287,341,375,457],"both":[190,362],"CD4":[191],"along":[195],"dose":[197],"dependent":[198],"secretion":[199,229],"IFN\u0263":[201,228,330],"patient":[203],"samples.":[204],"line":[206],"reports":[208],"PD-L1":[210,216,235,248,275,293,345,384],"induction":[211],"IFN\u0263,":[213],"upregulation":[217,338],"blasts":[220,251,296,312],"incubated":[221],"IFN\u0263.":[223],"Furthermore,":[224,260,368],"circulating":[225],"levels":[226,246,273],"flotetuzumab-treated":[231],"correlated":[233],"expression":[236,346],"blasts.":[239,350],"Notably,":[240],"primary":[241],"higher":[245,271,290],"malignant":[250],"susceptible":[254],"flotetuzumab-mediated":[256],"killing":[257],"vitro.":[259,367],"that":[262,373,391],"progressed":[263,374],"early":[264],"(within":[265],"two-weeks)":[266],"had":[270],"baseline":[272],"cells.":[278],"Interestingly,":[279],"number":[281],"residual":[285,379],"disease":[286,380],"proportion":[291],"positive":[294],"vs.":[297],"basal":[298],"levels.":[299],"Conclusions:":[301],"shown":[305],"evidence":[306],"against":[309],"CD123+":[310],"vivo,":[314],"associated":[315],"infiltration":[321],"activation":[323],"marrow,":[327],"enhanced":[329],"secretion,":[331],"which":[332],"turn":[334],"lead":[336],"T":[342],"Synergistic":[351],"cytotoxicity":[352],"was":[353],"after":[355],"cell":[359],"lines":[360],"CPI":[365],"or":[377,407,463],"tend":[381],"positive.":[385],"Taken":[386],"together,":[387],"these":[388],"data":[389],"suggest":[390],"combination":[392],"anti-PD1/PD-L1":[394],"therapy":[395],"enhance":[397],"effect":[399],"selected":[403],"relapsed":[406],"refractory":[408],"clinicaltrials.gov":[410],"NCT02152956":[411],"Disclosures":[415],"Fox:":[417],"Bristol":[418],"Myers-Squibb:":[419],"Consultancy,":[420,424,428,434,444,448,476],"Research":[421,425,429,435,445,477,538],"Funding;":[422,426,430,436,446],"AstraZeneca/MedImmune:":[423],"PerkinElmer:":[427],"Janssen/Johnson":[431],"Johnson:":[433],"Argos:":[437],"Consultancy;":[438,440,442,452,474],"Bayer:":[439],"Definiens:":[441],"OncoSec:":[443],"PrimeVax:":[447],"Equity":[449,454,491,508,524,530,536,543,548],"Ownership;":[450],"Peregrine:":[451],"UbiVac:":[453],"Ownership,":[455,509,537],"Membership":[456],"entity's":[459],"Board":[460],"Directors":[462],"advisory":[464],"committees,":[465],"Other:":[466],"Co-Founder":[467],"managing":[469],"Member":[470],"LLC;":[472],"Ventana/Roche:":[473],"Viralytics:":[475],"Funding.":[478,539],"Primo:":[479],"Vivia":[480,484],"Biotech:":[481,485],"Employment.":[482,486,499,503],"Ballesteros:":[483],"Sun:":[487],"Macrogenics":[488],"Inc:":[489],"Employment,":[490,507,523,529,535,542,547],"Ownership.":[492,525,531,544,549],"Lelievre:":[493],"Institut":[494],"de":[495],"recherches":[496],"international":[497],"Servier:":[498],"Baughman:":[500],"MacroGenics,":[501,521,527,533],"Inc.:":[502,522,528,534],"La":[504],"Motte-Mohs:":[505],"MacroGenics:":[506,541,546],"Patents":[510,517],"&":[511,518],"Royalties;":[512],"Sunnybrook":[513],"Health":[514],"Sciences":[515],"Centre:":[516],"Royalties.":[519],"Muth:":[520],"Moore:":[526],"Bonvini:":[532],"Wigginton:":[540],"Davidson-Moncada:":[545]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":7}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2019-12-05T00:00:00"}